The impact of dupilumab treatment on severe acute respiratory syndrome coronavirus 2-coronavirus disease 2019 antibody responses in patients with atopic dermatitis

Benjamin Ungar; Leore Lavin; Alexandra K. Golant; Alyssa Gontzes; Eden David; Yeriel D. Estrada; Giselle K. Singer; Ana B. Pavel; Emma Guttman-Yassky

doi:10.1016/j.anai.2022.03.019

The impact of dupilumab treatment on severe acute respiratory syndrome coronavirus 2-coronavirus disease 2019 antibody responses in patients with atopic dermatitis

Benjamin Ungar, Leore Lavin, Alexandra K. Golant, Alyssa Gontzes, Eden David, Yeriel D. Estrada, Giselle K. Singer, Ana B. Pavel, Emma Guttman-Yassky

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Original language	English
Pages (from-to)	734-736
Number of pages	3
Journal	Annals of Allergy, Asthma and Immunology
Volume	128
Issue number	6
DOIs	https://doi.org/10.1016/j.anai.2022.03.019
State	Published - Jun 2022

Access to Document

10.1016/j.anai.2022.03.019

Cite this

Ungar, B., Lavin, L., Golant, A. K., Gontzes, A., David, E., Estrada, Y. D., Singer, G. K., Pavel, A. B., & Guttman-Yassky, E. (2022). The impact of dupilumab treatment on severe acute respiratory syndrome coronavirus 2-coronavirus disease 2019 antibody responses in patients with atopic dermatitis. Annals of Allergy, Asthma and Immunology, 128(6), 734-736. https://doi.org/10.1016/j.anai.2022.03.019

@article{20ff2815086f45fbaaeb880dd60ecbb0,

title = "The impact of dupilumab treatment on severe acute respiratory syndrome coronavirus 2-coronavirus disease 2019 antibody responses in patients with atopic dermatitis",

author = "Benjamin Ungar and Leore Lavin and Golant, {Alexandra K.} and Alyssa Gontzes and Eden David and Estrada, {Yeriel D.} and Singer, {Giselle K.} and Pavel, {Ana B.} and Emma Guttman-Yassky",

note = "Funding Information: Funding: This work was supported by the Department of Dermatology at the Icahn School of Medicine at Mount Sinai and a grant from Regeneron and Sanofi. Patients were recruited from within the Department of Dermatology at the Icahn School of Medicine. All funding sources reviewed and accepted the study design and the manuscript, with minimal input from Regeneron and Sanofi. Research reported in this publication was also supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under award number U01AI152036. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Funding Information: Disclosures: Dr Guttman-Yassky is an employee of Mount Sinai and has received research funds (grants paid to the institution) from Abbvie, Amgen, AnaptysBio, AstraZeneca, Boehringer-Ingelheim, Cara Therapeutics, Innovaderm, Janssen, KAO, Kyowa Kirin, Leo Pharma, Pfizer, Regeneron Pharmaceuticals, Inc, and UCB; and is a consultant for Abbvie, Almirall, Amgen, Arena, Asana Biosciences, AstraZeneca, Boehringer-Ingelheim, Bristol-Meyers Squibb, Cara Therapeutics, Connect Pharma, Eli Lilly, EMD Serono, Evidera, Galderma, Ichnos Sciences, Incyte, Janssen Biotech, Kyowa Kirin, Leo Pharma, Pandion Therapeutics, Pfizer, Ribon, RAPT Therapeutics, Regeneron Pharmaceuticals, Inc, Sanofi, SATO Pharmaceutical, Siolta Therapeutics, Target PharmaSolutions, UCB, and Ventyx Biosciences. Dr Pavel is an employee of the University of Mississippi and has a research contract with Mount Sinai. The remaining authors have no conflicts of interest to report. Funding: This work was supported by the Department of Dermatology at the Icahn School of Medicine at Mount Sinai and a grant from Regeneron and Sanofi. Patients were recruited from within the Department of Dermatology at the Icahn School of Medicine. All funding sources reviewed and accepted the study design and the manuscript, with minimal input from Regeneron and Sanofi. Research reported in this publication was also supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under award number U01AI152036. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.",

year = "2022",

month = jun,

doi = "10.1016/j.anai.2022.03.019",

language = "English",

volume = "128",

pages = "734--736",

journal = "Annals of Allergy, Asthma and Immunology",

issn = "1081-1206",

publisher = "American College of Allergy, Asthma and Immunology",

number = "6",

}

Ungar, B, Lavin, L, Golant, AK, Gontzes, A, David, E, Estrada, YD, Singer, GK, Pavel, AB & Guttman-Yassky, E 2022, 'The impact of dupilumab treatment on severe acute respiratory syndrome coronavirus 2-coronavirus disease 2019 antibody responses in patients with atopic dermatitis', Annals of Allergy, Asthma and Immunology, vol. 128, no. 6, pp. 734-736. https://doi.org/10.1016/j.anai.2022.03.019

The impact of dupilumab treatment on severe acute respiratory syndrome coronavirus 2-coronavirus disease 2019 antibody responses in patients with atopic dermatitis. / Ungar, Benjamin; Lavin, Leore; Golant, Alexandra K. et al.

In: Annals of Allergy, Asthma and Immunology, Vol. 128, No. 6, 06.2022, p. 734-736.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - The impact of dupilumab treatment on severe acute respiratory syndrome coronavirus 2-coronavirus disease 2019 antibody responses in patients with atopic dermatitis

AU - Ungar, Benjamin

AU - Lavin, Leore

AU - Golant, Alexandra K.

AU - Gontzes, Alyssa

AU - David, Eden

AU - Estrada, Yeriel D.

AU - Singer, Giselle K.

AU - Pavel, Ana B.

AU - Guttman-Yassky, Emma

N1 - Funding Information: Funding: This work was supported by the Department of Dermatology at the Icahn School of Medicine at Mount Sinai and a grant from Regeneron and Sanofi. Patients were recruited from within the Department of Dermatology at the Icahn School of Medicine. All funding sources reviewed and accepted the study design and the manuscript, with minimal input from Regeneron and Sanofi. Research reported in this publication was also supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under award number U01AI152036. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Funding Information: Disclosures: Dr Guttman-Yassky is an employee of Mount Sinai and has received research funds (grants paid to the institution) from Abbvie, Amgen, AnaptysBio, AstraZeneca, Boehringer-Ingelheim, Cara Therapeutics, Innovaderm, Janssen, KAO, Kyowa Kirin, Leo Pharma, Pfizer, Regeneron Pharmaceuticals, Inc, and UCB; and is a consultant for Abbvie, Almirall, Amgen, Arena, Asana Biosciences, AstraZeneca, Boehringer-Ingelheim, Bristol-Meyers Squibb, Cara Therapeutics, Connect Pharma, Eli Lilly, EMD Serono, Evidera, Galderma, Ichnos Sciences, Incyte, Janssen Biotech, Kyowa Kirin, Leo Pharma, Pandion Therapeutics, Pfizer, Ribon, RAPT Therapeutics, Regeneron Pharmaceuticals, Inc, Sanofi, SATO Pharmaceutical, Siolta Therapeutics, Target PharmaSolutions, UCB, and Ventyx Biosciences. Dr Pavel is an employee of the University of Mississippi and has a research contract with Mount Sinai. The remaining authors have no conflicts of interest to report. Funding: This work was supported by the Department of Dermatology at the Icahn School of Medicine at Mount Sinai and a grant from Regeneron and Sanofi. Patients were recruited from within the Department of Dermatology at the Icahn School of Medicine. All funding sources reviewed and accepted the study design and the manuscript, with minimal input from Regeneron and Sanofi. Research reported in this publication was also supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under award number U01AI152036. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

PY - 2022/6

Y1 - 2022/6

UR - http://www.scopus.com/inward/record.url?scp=85128807160&partnerID=8YFLogxK

U2 - 10.1016/j.anai.2022.03.019

DO - 10.1016/j.anai.2022.03.019

M3 - Article

C2 - 35346880

AN - SCOPUS:85128807160

VL - 128

SP - 734

EP - 736

JO - Annals of Allergy, Asthma and Immunology

JF - Annals of Allergy, Asthma and Immunology

SN - 1081-1206

IS - 6

ER -